|
[1] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020.[Online ahead of print]
|
|
[2] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
|
|
[3] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
|
[4] MOHAMMED E,ARUN JS,JACOB G,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014.
|
|
[5] GASTALDELLI A,CUSI K. From NASH to diabetes and from diabetes to NASH:Mechanisms and treatment options[J].JHEP Rep,2019,1(4):312-328.
|
|
[6] AMARAPURKAR DN,HASHIMOTO E,LESMANA LA,et al.How common is non-alcoholic fatty liver disease in the AsiaPacific region and are there local differences?[J]. J Gastroenterol Hepatol,2007,22(6):788-793.
|
|
[7] POLYZOS SA,KOUNTOURAS J,MANTZOROS CS. Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J]. Metabolism,2019,92:82-97.
|
|
[8] BRIL F,CUSI K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:A call to action[J]. Diabetes Care,2017,40(3):419-430.
|
|
[9] BRIL F,CUSI K. Nonalcoholic fatty liver disease:The new complication of type 2 diabetes mel itus[J]. Endocrinol Metab Clin North Am,2016,45(4):765-781.
|
|
[10] MARCHESINI G,DAY CP,DUFOUR JF,et al. EASL-EASDEASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.
|
|
[11] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108.
|
|
[12] BIAN H,ZHU X,XIA M,et al. Impact of type 2 diabetes on nonalcoholic steatohe patitis and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocr Pract,2020,26(4):444-453.
|
|
[13] PORIES WJ,MACDONALD KG Jr,MORGAN EJ,et al. Surgical treatment of obesity and its effect on diabetes:10-y follow-up[J]. Am J Clin Nutr,1992,55(2 Suppl):582s-585s.
|
|
[14] LEAN ME,LESLIE WS,BARNES AC,et al. Primary care-led weight management for remission of type 2 diabetes(DiRECT):An open-label,cluster-randomised trial[J]. Lancet,2018,391(10120):541-551.
|
|
[15] LEAN M,LESLIE WS,BARNES AC,et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes:2-year results of the DiRECT openlabel,cluster-randomised trial[J]. Lancet Diabetes Endocrinol,2019,7(5):344-355.
|
|
[16] TAYLOR R,AL-MRABEH A,SATTAR N. Understanding the mechanisms of reversal of type 2 diabetes[J]. Lancet Diabetes Endocrinol,2019,7(9):726-736.
|
|
[17] TAYLOR R,BARNES AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one[J]. Diabet Med,2019,36(3):308-315.
|
|
[18] PETRICK JL,KELLY SP,ALTEKRUSE SF,et al. Future of hepatocellular carcinoma incidence in the united states forecast through 2030[J]. J Clin Oncol,2016,34(15):1787-1794.
|
|
[19] HESTER D,GOLABI P,PAIK J,et al. Among medicare patients with hepatocellular carcinoma,non-alcoholic fatty liver disease is the most common etiology and cause of mortality[J]. J Clin Gastroenterol,2020,54(5):459-467.
|
|
[20] ANSTEE QM,REEVES HL,KOTSILITI E,et al. From NASH to HCC:Current concepts and future challenges[J]. Nat Rev Gastroenterol Hepatol,2019,16(7):411-428.
|
|
[21] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
|
|
[22] ALUKAL JJ,THULUVATH PJ. Reversal of NASH fibrosis with pharmacotherapy[J]. Hepatol Int,2019,13(5):534-545.
|
|
[23] FIORUCCI S,BIAGIOLI M,DISTRUTTI E. Future trends in the treatment of non-alcoholic steatohepatitis[J]. Pharmacol Res,2018,134:289-298.
|
|
[24] JOHNSTON MP,PATEL J,BYRNE CD. Multi-drug approaches to NASH:What's in the development pipeline?[J]. Expert Opin Investig Drugs,2020,29(2):143-150.
|
DownLoad: